tbuckley/cabot-search huggingface dataset:
Comparison of prognostic impact between metabolic and radiologic response after induction chemotherapy for resectable malignant pleural mesothelioma: A multicenter study.
Authors: Yasuhiro Tsutani, Teruhisa Takuwa, Yoshihiro Miyata, Kazuya Fukuoka, Seiki Hasegawa, Takashi Nakano, Morihito Okada
Journal: Journal of Clinical Oncology (2012)

7031 Background: Induction chemotherapy followed by extrapleural pneumonectomy (EPP) for resectable malignant pleural mesothelioma (MPM) is controversial. To select optimal candidates for EPP, we evaluates the usefulness of metabolic response on fluorodeoxyglucose-positron emission tomography (FDG-PET) compared with radiologic response on high-resolution computed tomography (HRCT) after induction chemotherapy to predict prognosis for patients with resectable MPM who underwent EPP in the setting of multicenter study. Methods: We performed HRCT and FDG-PET before and after induction platinum-based chemotherapy on 50 patients with clinical T1-3 N0-2 M0 MPM who underwent EPP ± postoperative hemithoracic radiation. A decrease of more than 30% in tumor maximum standardized uptake value (SUVmax) was defined as a metabolic responder. Radiologic response using modified RECIST or metabolic response and surgical results were analyzed. Results: In all cohort patients, median overall survival (OS) from diagnosis was 20.5 month (95% confidence interval [CI], 15.0-26.0 month). Fourteen patients were classified as metabolic responders (28%) and 36 as non-responders (72%). Metabolic responders significantly correlated to OS with median OS for metabolic responders of not reached (3-year OS of 60.0%) versus 18.7 month (95% CI, 13.3-24.2 month, 3-year OS of 26.5%) for non-responders (P = .025). No correlation was observed between OS and radiologic response with median OS for radiologic responders of 25.7 month (n = 20, 95% CI, 14.5-37.0 month, 3-year OS of 35.8%) versus 17.7 month (n = 30, 95% CI, 12.8-22.6 month, 3-year OS of 35.1%) for non-responder (p = .216). Based on the multivariate Cox analyses, decreased SUVmax (%) (p = .010) was a significantly independent factor for OS as well as epithelioid subtype (p = .044). Conclusions: Metabolic response on FDG-PET has higher predictive value of prognosis than radiologic response on HRCT after induction chemotherapy for patients with resectable MPM. Patients with metabolic responder and/or epithelioid subtype can be good candidates for EPP after induction chemotherapy.
<i>Notes from the Field:</i> Targeted Biomonitoring for GenX and Other Per- and Polyfluoroalkyl Substances Following Detection of Drinking Water Contamination — North Carolina, 2018
Authors: Jamie R. Pritchett, Jessica L. Rinsky, Beth Dittman, Ariel Christensen, Rick Langley, Zack Moore, Aaron T. Fleischauer, Kate Koehler, Antonia M. Calafat, Rachel Rogers, Laconial Esters, Rodney Jenkins, Faye Collins, Debra Conner, Patrick Breysse
Journal: MMWR Morbidity and Mortality Weekly Report (2019)
“Medicare for all” is unlikely to cause the surge in hospital use that critics warn of, study says
Authors: Elisabeth Mahase
Journal: BMJ (2019)

A new study has provided evidence that “Medicare for all” in the United States will not require an expansion of hospitals.

Healthcare policy—and specifically “Medicare for all”—has become one of the main matters debated among Democratic party candidates battling to stand against President Donald Trump in the 2020 US election.

Medicare for all—long supported by senator for Vermont Bernie Sanders, and more recently backed by other candidates including Massachusetts senator Elizabeth Warren—would move the US towards a healthcare system with greater similarities to the NHS, with the government paying for healthcare (through taxes), rather than insurance companies.

Some analysts have suggested, however, that the policy would …
Incidence of bone fracture in Japanese patients receiving long-term hormone therapy for prostate cancer.
Authors: Hiroji Uemura, Hideo Fusayasu, Shinji Ohtake, Narihiko Hayashi, Yumiko Yokomizo, Yasuhide Miyoshi, Yoshinobu Kubota, Kouji Izumi
Journal: Journal of Clinical Oncology (2013)

e16098 Background: For patients with advanced prostate cancer, long-term treatment of androgen deprivation has been conventionally performed. Among the adverse events such as hormonal therapy, bone fracture due to osteoporosis or metastatsis is one of indispensable events. We assessed the frequency of bone fractures in Japanese patients received hormonal therapy. Methods: Between 2000 and 2010, 1,108 Japanese patients were treated with hormonal therapy including GnRH agonist plus anti-androgens or GnRH agonist alone at Yokohama City University Hospital. Of those patients, 48 patients (4.3%) had bone fractures during their treatment. In this retrospective study, we examined the association of bone fracture with the long-term hormonal therapy by investigating the duration of hormonal therapy, fracture sites, and the occurrence of fracture in castration resistant prostate cancer (CRPC) patients. Results: The median age of the patients with fracture was 77 (60-85) years; the median duration from the start of hormonal therapy to fracture was 29.4 (5.4-110.4) months. Eight patients with CRPC had pathological fractures at bone metastases. With respect of fracture sites, 22 patients (46%) had spinal fractures and 10 patients (21%) had fracture of lower legs. Of 8 CRPC patients, 7 patients had spinal fracture after long-term hormonal therapy (median: 38.6 months, range: 15.7-99.1 months). Conclusions: Japanese patients with prostate cancer treated with hormonal therapy have lower risk for bone fracture compared with those in western countries and USA, and interestingly, it is recognized that vertebral body is vulnerable to fracture in Japanese, especially in CRPC patients treated for long-term hormonal therapy. Because bone fracture in patients with prostate cancer endanger their prognosis, the bone management how to prevent bone fracture is very important during hormonal therapy. For the purpose of it, more detailed analysis in this retrospective study should be required.
Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors
Authors: Jia-Cheng Lu, Hai-Ying Zeng, Qi-Man Sun, Qing-Nan Meng, Xiao-Yong Huang, Peng-Fei Zhang, Xuan Yang, Rui Peng, Chao Gao, Chuan-Yuan Wei, Ying-Hao Shen, Jia-Bing Cai, Rui-Zhao Dong, Ying-Hong Shi, Hui-Chuan Sun, Yujiang G. Shi, Jian Zhou, Jia Fan, Ai-Wu Ke, Liu-Xiao Yang, Guo-Ming Shi
Journal: Theranostics (2019)

Rationale: PD1/PD-L1 immune checkpoint inhibitors have shown promising results for several malignancies.However, PD1/PD-L1 signaling and its therapeutic significance remains largely unknown in intrahepatic cholangiocarcinoma (ICC) cases with complex etiology.Methods: We investigated the expression and clinical significance of CD3 and PD1/PD-L1 in 320 ICC patients with different risk factors.In addition, we retrospectively analyzed 7 advanced ICC patients who were treated with PD1 inhibitor.Results: The cohort comprised 233 patients with HBV infection, 18 patients with hepatolithiasis, and 76 patients with undetermined risk factors.PD-L1 was mainly expressed in tumor cells, while CD3 and PD1 were expressed in infiltrating lymphocytes of tumor tissues.PD1/PD-L1 signals were activated in tumor tissues, and expression was positively correlated with HBV infection and lymph node invasion.More PD1 + T cells and higher PD-L1 expression were observed in tumor tissues of ICC patients with HBV infection compared to patients with hepatolithiasis or undetermined risk factors.More PD1 + T cells and/or high PD-L1 expression negatively impacted the prognosis of patients with HBV infection but not those with hepatolithiasis.Multivariate analysis showed PD1/PD-L1 expression was an independent indicator of ICC patient prognosis.Advanced ICC patients with HBV infection and less PD1 + T cells tended to have good response to anti-PD1 therapy.Conclusion: Hyperactivated PD1/PD-L1 signals in tumor tissues are a negative prognostic marker for ICCs after resection.HBV infection-and hepatolithiasis-related ICCs have distinct PD1/PD-L1 profiles.Further, PD1 + T cells could be used as a biomarker to predict prognosis and assay the efficiency of anti-PD1 immunotherapy in ICC patients with HBV infection.
Phase II study of conventional fractionated radiotherapy versus hyper-fractionated accelerated radiotherapy concomitant with low dose gemcitabine for patients with pancreatic cancer
Authors: K. Maemura, S. Takao, H. Shinchi, H. Noma, Y. Hiraki, M. Nakajo, T. Aikou
Journal: Journal of Clinical Oncology (2006)

14017 Background: Concurrent radiotherapy and chemotherapy with gemcitabine (GEM) has been reported to improve the median survival of patients with unresectable pancreatic cancer. Although hyperfractionated accelerated radiotherapy (HART) was administered to pancreatic cancer recently, the efficacy is unclear. Phase II study was conducted to evaluate the efficacy and the toxicity of HART concomitant with twice-weekly low dose GEM compared with conventionally fractionated radiotherapy (CRT) for unresectable pancreatic cancer. Methods: Between April 2001 and April 2004, 34 untreated eligible patients with histologically proven unresectable pancreatic cancer were enrolled. In CRT group (n=15), 50.4Gy was delivered in 28 fractions of 1.8Gy/day. In HART group (n=19), 50Gy was delivered in 40 fractions of 1.25Gy twice a day. All patients were treated with conformal radiation using 5mm multileaf collimeter. Concurrent chemotherapy with GEM (40mg/m 2 ) was administered twice a week to both groups. Chemotherapy was suspended for Grade 3 toxicities or increase in temperature more than 38 °C. Response evaluations were conducted at six weeks after the treatment. Maintenance chemotherapy composed of GEM (1000mg/m 2 /week) for 3weeks was repeated every 4 weeks thereafter. Results: The median survival time (MST) was 11.3 months in CRT group and 12.9 months in HART group. The 1- and 2-year survival rates were 42.9% and 28.6% in CRT group, 52.9% and 17.6% in HART group. There was no significant difference in response rate between CRT and HART group (35.7% vs. HART; 35.3%). The median time to progression (TTP) was significantly prolonged in HART group (9.7months) compared with CRT group (5.9 months) (p=0.02). Overall treatment time was significantly shorter in HART group (37days) than CRT group (45days) (p=0.002). There was no significant deference in toxicity between CRT and HART group. Conclusions: HART concomitant with low dose GEM was well tolerated with acceptable toxicity and prolonged median TTP and MST with shortening of treatment time compared with conventional radio-chemotherapy. This regimen appears to be one of the crucial therapies for patients with unresectable pancreatic cancer. No significant financial relationships to disclose.
Attenuated Acceleration to Leukemia after Ezh2 Loss in Nup98‐HoxD13 (NHD13) Myelodysplastic Syndrome
Authors: Victoria Y. Ling, Jesslyn Saw, Cedric S. Tremblay, Stefan E. Sonderegger, Emma Toulmin, Jacqueline Boyle, Sung Kai Chiu, Steven W. Lane, Stephen B. Ting, David J. Curtis
Journal: HemaSphere (2019)

Supplemental Digital Content is available in the text.
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial
Authors: Kayvon Modjarrad, Christine C Roberts, Kristin T Mills, Amy R Castellano, Kristopher Paolino, Kar Muthumani, Emma L Reuschel, Merlin L Robb, Trina Racine, Myoung-don Oh, Claude Lamarre, Faraz I Zaidi, Jean Boyer, Sagar B Kudchodkar, Moonsup Jeong, Janice M Darden, Young K Park, Paul T Scott, Celine Remigio, Ajay P Parikh, Megan C Wise, Ami Patel, Elizabeth K Duperret, Kevin Y Kim, Hyeree Choi, Scott White, Mark Bagarazzi, Jeanine M May, Deborah Kane, Hyojin Lee, Gary Kobinger, Nelson L Michael, David B Weiner, Stephen J Thomas, Joel N Maslow
Journal: The Lancet Infectious Diseases (2019)
Lung Cancer–Related Mortality With Inhaled Insulin or a Comparator: Follow-Up Study of patients previously enrolled in Exubera Controlled Clinical Trials (FUSE) Final Results
Authors: Nicolle M. Gatto, Daniel O. Koralek, Michael B. Bracken, William T. Duggan, Joanna Lem, Sol Klioze, Gary G. Koch, Robert A. Wise, Roger B. Cohen, Neville C. Jackson
Journal: Diabetes Care (2019)

The Follow-Up Study of patients previously enrolled in Exubera controlled clinical trials (FUSE) was designed to evaluate whether patients previously treated with Exubera (EXU; insulin human [rDNA origin], inhaled powder) in controlled clinical trials died because of incident primary lung cancer at a substantially higher rate than patients treated with a comparator.FUSE is a hybrid, randomized, controlled trial/cohort study including participants of 17 prior EXU clinical trials. Pooled patient data from these trials were used, and the subset of patients enrolled in the follow-up cohort study was followed prospectively for 2 years in order to evaluate the incidence of fatal and nonfatal primary lung cancers and all-cause mortality.There were 24,409 person-years (PY) of observation among 7,439 trial patients, with 4,017 PY (16.5%) from the period after the trials but before the prospective follow-up and 5,299 PY (21.7%) from the prospective follow-up. Just over half of the 2,631 patients (51.6%) in the prospective follow-up were randomized to EXU in the original trial. The incidence density ratio was 2.8 (95% CI 0.5, 28.5) for lung cancer-related mortality and 3.7 (95% CI 1.0, 20.7) for incident primary lung cancer. The hazard ratio for all-cause mortality was 0.81 (95% CI 0.60, 1.10).These data cannot exclude an increased risk of lung cancer-related mortality associated with EXU use. If real, the absolute increased risk of lung cancer-related mortality was small (0.48 cases per 1,000 PY). For all-cause mortality-the most reliably measured end point with the clearest interpretation-EXU users did not experience an excess all-cause death rate (relative or absolute) compared with users of other diabetes treatments over the study period.
Prolonged Arsenic Trioxide (ATO) and All- Trans Retinoic Acid (ATRA) Therapy for Relapsed Acute Promyelocytic Leukemia
Authors: Laura Cicconi, Massimo Breccia, Luca Franceschini, Roberto Latagliata, Matteo Molica, Manuela Rizzo, Mariadomenica Divona, Licia Iaccarino, Tiziana Ottone, Valentina Alfonso, Robin Foa, Maria Teresa Voso, Francesco Lo Coco
Journal: Blood (2017)
Supporting autistic flourishing
Authors: Vikram K. Jaswal, Nameera Akhtar
Journal: Behavioral and Brain Sciences (2019)

Abstract In response to the 32 commentaries, we clarify and extend two of the central arguments in our target article: (1) Social motivation is a dynamic, emergent process, not a static characteristic of individuals, and (2) autistic perspectives are essential to the study of autistic social motivation. We elaborate on how taking these two arguments seriously can contribute to a more accurate, humane, and useful science of autism.
A Bloody Mystery
Authors: Jean M. Connors, Kathryn A. Britton
Journal: New England Journal of Medicine (2009)

A 62-year-old woman presented to the urgent care clinic with gingival bleeding after periodontal scaling of her lower right second molar. She had undergone the procedure 5 hours before presentation, and the bleeding had persisted despite the application of pressure and ice. The patient recalled a similar episode that had occurred approximately 6 months earlier, also after a periodontal . . .
An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease
Authors: Filomena Daraio, Emilia Giugliano, Carmen Fava, Roberta Lorenzatti, Marta Varotto, Davide Barberio, Simona Bernardi, Barbara Izzo, Santa Errichiello, Maria Teresa Bochicchio, Claudia Venturi, Francesco Albano, Giuseppe Saglio, Fabrizio Pane, Giovanni Martinelli, Giorgina Specchia, Domenico Russo, Enrico Marco Gottardi
Journal: Blood (2017)
Comorbidity, characteristics, and survival of gastric cancer patients at a VA medical center.
Authors: Trent P. Wang, Tanganyika Barnes, Arpita Gandhi, Fengming Zhong, Victor Tsu-Shih Chang, Melanie L. Gonzalez, Lucy Cheng, Lourdes Duque, Janet Cogswell, Basil Kasimis
Journal: Journal of Clinical Oncology (2012)

e14727 Background: This is to study whether comorbidity indices predict survival in gastric cancer patients (pts). Methods: In an IRB approved protocol, we reviewed the records of pts diagnosed with gastric cancer at a VA Medical Center from 3/1/2000 to 3/31/2011. Comorbidity was assessed with four comorbidity indices, the Charlson Comorbidity Index (CMI), the Kaplan-Feinstein Index (KFI), the Cumulative Illness Rating Scale (CIRS), and VA Comorbidity Scale (VACS). Demographics, stage, histology, grade, weight (wt) loss, hemoglobin (HGB), ALB, Total bilirubin (TBili), creatinine at diagnosis, alcohol or tobacco use, past gastric surgery (pSx), and surgical resection (Sx) were also reviewed. COX survival analysis was performed. Results: There were 49 patients. All were men. 23 (46.9%) pts were Caucasian, 25 (51%) African American and 1 (2%) Hispanic. The median (M) age at diagnosis was 70 years (range 43-90). Median survival was 321 days (4-4221). 17 (35.5%) pts has localized disease (stage I/II), and 31 (64.5 %) advanced disease (stage III/IV). 2 (4%) pts had grade1, 12 (26%) grade 2, 32 (68%) grade 3, and 1 (2.1%) grade 4. M HGB was 12.1 g/dl (range 5.5-16.9), MCV 85.4 fl (59-104), albumin 3.6 g/dl (1.8-4.6), TBili 0.5 mg/dl (0.2-5.1) and creatinine 1 mg/dl (0.7-1.6). M CMI 4.7 (1.1-10.8), CIRS15 5 (0-12), CIRS16 9 (0-19), CIRS17 1.6 (0-2.5), CIRS18 0 ( 0-4), CIRS19 0 (0-1), KFI 3 (0-3), VACS 4 (0-12) Demographic features included alcohol use (51%), M tobacco use 25 PPY (0-80), and M wt loss 9% (0-25) and pSX 5 (10%). 22 pts (47%) has Sx. In univariate survival analysis, only wt loss (p&lt;0.013), stage (p&lt;0.001), grade (p&lt;0.001), Tbil (p&lt;0.003), and Sx (p&lt;0.003) were significant in predicting survival. In multivariate survival analyses, none were significant for predicting survival. Conclusions: Comorbidity did not contribute to the survival of gastric ca pts in this population. More research in a larger sample is needed. Supported by the New Jersey Commission for Cancer Research.
Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial
Authors: Joshua Rhein, Kathy Huppler Hullsiek, Lillian Tugume, Edwin Nuwagira, Edward Mpoza, Emily E Evans, Reuben Kiggundu, Katelyn A Pastick, Kenneth Ssebambulidde, Andrew Akampurira, Darlisha A Williams, Ananta S Bangdiwala, Mahsa Abassi, Abdu K Musubire, Melanie R Nicol, Conrad Muzoora, David B Meya, David R Boulware, Joshua Rhein, Kathy Huppler Hullsiek, Lillian Tugume, Edwin Nuwagira, Edward Mpoza, Emily E Evans, Reuben Kiggundu, Katelyn A Pastick, Kenneth Ssebambulidde, Andrew Akampurira, Darlisha A Williams, Ananta S Bangdiwala, Mahsa Abassi, Abdu K Musubire, Melanie R Nicol, Conrad Muzoora, David B Meya, David R Boulware, Jane Francis Ndyetukira, Cynthia Ahimbisibwe, Florence Kugonza, Carolyne Namuju, Alisat Sadiq, Alice Namudde, James Mwesigye, Kiiza K Tadeo, Paul Kirumira, Michael Okirwoth, Tonny Luggya, Julian Kaboggoza, Eva Laker, Leo Atwine, Davis Muganzi, Stewart Walukaga, Bilal Jawed, Matthew Merry, Anna Stadelman, Nicole Stephens, Andrew G Flynn, Ayako W Fujita, Richard Kwizera, Liliane Mukaremera, Sarah M Lofgren, Fiona V Cresswell, Bozena M Morawski, Nathan C Bahr, Kirsten Nielsen
Journal: The Lancet Infectious Diseases (2019)
Bendamustine, Carfilzomib, and Melphalan (BCM) Conditioning Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Feasibility Study
Authors: A. Samer Al-Homsi, Marlee Muilenburg, Kelli Cole, Muneer H. Abidi, Stephanie F. Williams
Journal: Blood (2016)
Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow‐Up of Population Cohorts
Authors: Fredrik Åberg, Pauli Puukka, Veikko Salomaa, Satu Männistö, Annamari Lundqvist, Liisa Valsta, Markus Perola, Martti Färkkilä, Antti Jula
Journal: Hepatology (2019)

Background and Aims The effects of alcohol use in nonalcoholic fatty liver disease are unclear. We investigated the impact of alcohol use in fatty liver disease on incident liver, cardiovascular, and malignant disease, as well as death. Approach and Results Our study comprised 8,345 persons with hepatic steatosis (fatty liver index &gt;60) who participated in health‐examination surveys (FINRISK 1992‐2012 or Health 2000), with available data on baseline alcohol intake. Main exclusions were baseline clinical liver disease, viral hepatitis, ethanol intake &gt;50 g/day, and current abstainers. Data were linked with national registers for hospital admissions, malignancies, and death regarding liver, cardiovascular, and malignant disease, as well as all‐cause death. Adjustment were for multiple confounders. Alcohol consumption showed a dose‐dependent risk increase for incident advanced liver disease and malignancies. Consuming 10‐19 g/day of alcohol in general or 0‐9 g/day as nonwine beverages doubled the risk for advanced liver disease compared to lifetime abstainers. In contrast, alcohol intake up to 49 g/day was associated with a 22%‐40% reduction of incident cardiovascular disease (CVD). We observed a J‐shaped association between alcohol intake and all‐cause death with a maximal risk reduction of 21% (95% confidence interval, 5%‐34%) at alcohol intake of 0‐9 g/day compared to lifetime abstainers. However, these benefits on CVD and mortality were only observed in never smokers. Alcohol intake &gt;30 g/day yielded increased risk estimates for mortality compared to lifetime abstainers. In a subpopulation with longitudinal data, alcohol intake remained stable over time in &gt;80% of subjects. Conclusions Even low alcohol intake in fatty liver disease is associated with increased risks for advanced liver disease and cancer. Low to moderate alcohol use is associated with reduced mortality and CVD risk but only among never smokers.
Next Generation Sequencing of Immunized Mouse Splenocytes to Develop an Anti-TIM3 Chimeric Antigen Receptor for Acute Myeloid Leukemia
Authors: Justin C. Boucher, Paresh Vishwasrao, Lawrence Guan, Bishwas Shrestha, Gongbo Li, Scott Christley, Lindsay G. Cowell, Jared Ostmeyer, William H. Rounds, Inimary T. Toby, Marco L. Davila
Journal: Blood (2017)
Gut microbiota–bile acid–interleukin-22 axis orchestrates polycystic ovary syndrome
Authors: Xinyu Qi, Chuyu Yun, Lulu Sun, Jialin Xia, Qing Wu, Ying Wang, Lina Wang, Yangming Zhang, Xianyi Liang, Liying Wang, Frank J. Gonzalez, Andrew D. Patterson, Huiying Liu, Liangshan Mu, Zehong Zhou, Yue Zhao, Rong Li, Ping Liu, Chao Zhong, Yanli Pang, Changtao Jiang, Jie Qiao
Journal: Nature Medicine (2019)